Company Overview of Invitae Corporation
Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare. It processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for physicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. The company provides a single diagnostic service comprising approximately 200 genes for various genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology, and pediatrics. It also offers solutions that enable sharing...
458 Brannan Street
San Francisco, CA 94107
Founded in 2010
Key Executives for Invitae Corporation
Chairman, Chief Executive Officer and Member of Strategy Team
Total Annual Compensation: $203.7K
Co-Founder, President, Chief Operating Officer, Member of Strategy Team and Director
Total Annual Compensation: $281.9K
Chief Commercial Officer and Member of Strategy Team
Total Annual Compensation: $286.6K
Compensation as of Fiscal Year 2014.
Invitae Corporation Key Developments
InVitae Corporation Seeks Acquisitions
Jan 12 15
InVitae Corporation has filed for an IPO in the amount of $86.25 million. They may use the net proceeds from this offering to license, acquire or invest in complementary business, technologies, products or assets.
InVitae Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 05:00 PM
Jan 6 15
InVitae Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 05:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Randy Scott, Chairman and CEO.
Invitae Corporation and Nanopharmacia Announce Partnership to Make Reliable, Fast and Affordable Hereditary Cancer Genetic Testing Broadly Available in Mexico
Jul 30 14
Invitae Corporation and Nanopharmacia announced an exclusive partnership to make Invitae's genetic tests for the management of hereditary cancers broadly available throughout Mexico. In addition, the partnership includes access on a non-exclusive basis in Costa Rica and Panama. Nanopharmacia will offer Invitae's hereditary cancer panels and BRCA1/BRCA2 offering to a wide network of onco-geneticists and medical and surgical oncologists. Invitae's oncology offering includes: Single gene BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis; High-risk hereditary breast cancer panel (6 genes); Women's hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer); Hereditary cancer syndromes panel (29 genes); Hereditary Pancreatic Cancer Panel (17 genes); Additional hereditary cancer panels are available, including testing for Lynch Syndrome and colon cancers. The partnership includes access for advanced next generation genetic testing in Mexico through a network of approximately 800 oncology professionals in Mexico, as well as in Costa Rica and Panama.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 13, 2014